Recall of PROSTIVA RF Model 8930 Generator (Used for minimally invasive treatment for patients with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH))

According to Department of Health, Therapeutic Goods Administration, this recall involved a device in Australia that was produced by Medtronic Australasia Pty Ltd.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
    Recall
  • Event ID
    RC-2013-RN-00280-1
  • Event Risk Class
    Class II
  • Event Initiated Date
    2013-03-28
  • Event Country
  • Event Source
    DHTGA
  • Event Source URL
  • Notes / Alerts
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Extra notes in the data
  • Reason
    Medtronic has found through device testing that if the foot switch is not connected to the model 8930 rf generator, there is the potential for an electrostatic discharge on the foot switch connector port to toggle the generator rf output on or off. this behaviour mimics the performance of operation of the footswitch.
  • Action
    Medtronic is sending an insulating cap for placing over the foot switch connector port located on the rear panel of the Model 8930 RF Generator. The insulating cap is not necessary if the foot switch is connected.

Device

  • Model / Serial
    PROSTIVA RF Model 8930 Generator (Used for minimally invasive treatment for patients with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH))ARTG Number: 137006
  • Manufacturer

Manufacturer

  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DHTGA